Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep1140 | Thyroid | ECE2022

Sonographic features of autoimmune thyroiditis - a clinical perspective

Anandappa Samantha , Velusamy Anand

Autoimmune Hypothyroidism is a common clinical condition with a suggested prevalence of up to 12% of the population. The subsequent enlargement of the thyroid gland caused by circulating thyroid antibodies can cause neck discomfort warranting a referral to the thyroid ultrasound (USG) clinic. The USG characteristics of autoimmune hypothyroidism can be challenging to grade and the atypical appearances often makes it difficult to exclude a mitotic lesion. We have set forward few...

ea0082wa1 | Workshop A: Disorders of the hypothalamus and pituitary | SFEEU2022

Yet another case of Diabetes Insipidus!

Salema Valmiki , Velusamy Anand

26year old Human rights activist being evaluated for left hip and thigh pain over the preceding 7 months, was referred to our services in November 2015 with headache, secondary amenorrhoea and raised prolactin levels. The headache which was mainly frontal started a few months ago and coincided with the amenorrhoea. She did not report visual disturbances or lactation. She also described the feeling of increased thirst and increased urinary frequency over this period. Apart from...

ea0055cb16 | Additional Cases | SFEEU2018

DHEA: is it fountain of youth or medical need?

Kumar Rakshit , Hafeez Saba , Velusamy Anand

We present here a case of 70 year old female, seen in endocrine clinic for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression after prolonged glucocorticoid use. History revealed that she had prolonged use of prednisolone for her asthma in the past. In 2011, Prednisolone was stopped but she had to be started on Hydrocortisone replacement due to HPA axis suppression. She was taking Hydrocortisone 20 mg BD. Trials to wean her off Hydrocortisone failed due to ongoing tiredness...

ea0073aep841 | Late Breaking | ECE2021

Natural course and surveillance of non-functioning pituitary microadenomas

Iyer Rishi , Kumar Rakshit , Velusamy Anand

In the current era of multi-modal imaging being performed for various pathologies, incidental non-functioning pituitary microadenomas (NFPAs) are being increasingly identified. The available literature and guidance is limited on the long-term surveillance and monitoring and hence there is a wide variation in clinical practice across the UK. We conducted a retrospective study in our institution to compare the outcome in our cohort to the current literature.<p class="abstext...

ea0077p222 | Neuroendocrinology and Pituitary | SFEBES2021

SDHD missense pathogenic variants: not always benign

Haboosh Sara , Carroll Paul , Izatt Louise , Quinn Mark , Velusamy Anand

Pathogenic variants in the SDHx genes are responsible for ~20% of familial Phaeochromocytoma/Paraganglioma (PPGL) tumours. Metastatic disease is lower in SDHD in comparison to SDHA, B and C mutations. Although the genotype-phenotype relationship is not well established it is considered that truncating SDHD pathogenic variants have a higher risk of causing disease in comparison to missense variants. We present two cases of metastatic paraganglioma in patients with heterozygous ...

ea0055wc2 | Workshop C: Disorders of the thyroid gland (I) | SFEEU2018

Toxic nodule: wait or treat?

Hafeez Saba , Kumar Rakshit , Velusamy Anand , Powrie Jake , Carroll Paul

68 years old female initially referred to endocrine clinic in November 2016 for assessment of fluctuating thyroid function. She had a history of long standing primary hypothyroidism, stable on treatment with 100 mcg Levothyroxine. In last one year, Levothyroxine was tapered and stopped due to persistent suppression of TSH and high normal Free T4. Last tests showed TSH of <0.01mIU/l and Free T4 of 27.1 pmol/l. She had ongoing complaints of feeling increasingly tired and gen...

ea0082oc2 | Oral Communications | SFEEU2022

A case of multiple paragangliomas in a chronic hypoxic patient with congenital heart disease

Khanam Amina , Tharma Tharani , Joshi Mamta , Velusamy Anand , Carroll Paul

A 50-year-old female with complex chronic hypoxic congenital heart disease was incidentally identified with a 2 cm extra-vesicular nodule of the bladder during a surveillance ultrasound scan. Suspicious of a bladder carcinoma she uneventfully underwent open partial cystectomy. Histology confirmed a bladder paraganglioma with local lymph node invasion. Post-operative biochemical work-up disclosed raised plasma metanephrine”s: normetadrenaline 7073 pmol/l (120-1180 pmol/l),...

ea0065p139 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Clinical spectrum of endocrine toxicities of Immune checkpoint therapy: single centre experience

Joshi Mamta , Duffy Leo , Velusamy Anand , Papa Sophie , Carroll Paul

Introduction: Checkpoint inhibitor (CPI) related endocrine toxicities are increasingly commonly with the use of these new cancer agents. With one of the largest cancer departments in UK, we studied the clinical management and outcome of patients who developed different endocrine toxicities over the last five years, with the use of CTLA-4, PD-1 and PDL-1 agents.Methods: All patients treated with CPI between 1 Jan 2014 to 31 Jan 2019 were included for the ...

ea0065p399 | Thyroid | SFEBES2019

Factors involved in the relapse of autoimmune thyrotoxicosis following first line treatment with anti-thyroid medication

Anandappa Samantha , Venkatesh Samyukta , McGowan Barbara , Carroll Paul , Velusamy Anand

Aim: Anti-thyroid treatment with carbimazole or propylthiouracil is the first-line treatment for autoimmune thyrotoxicosis in the UK. Following 12–18 months treatment there is a significant relapse rate (at least 50%). This study analysed the demographics and clinical features of 100 patients with relapsed thyrotoxicosis to examine which variables are predictive of relapse.Methods: This retrospective study included adult patients identified using ou...

ea0063p1041 | Interdisciplinary Endocrinology 2 | ECE2019

Identification, management and outcome of endocrine toxicities related to immune checkpoint inhibitors

Duffy Leo , Joshi Mamta , Velusamy Anand , Papa Sophie , Carroll Paul

Introduction: Immunotherapy has become standard treatment for an increasingly wide range of cancers. Checkpoint inhibitors (ICT; CTLA4, PD1 & PD-L-1) can cause endocrine toxicity, principally affecting the pituitary and thyroid glands. We have studied the clinical management and outcome of patients with endocrine adverse effects over 5 years at our cancer centre.Methods: All patients treated with ICT agents between 1 Jan 2014 to 31 Jan 2019 were incl...